Calgary, AB, Canada, January 26, 2016 - Orpyx Medical Technologies Inc. announced today that the New Zealand intellectual property office has awarded Orpyx an important patent related to the company’s foundation technology. The “Peripheral Sensory and Supersensory Replacement System” patent covers key inventions used in both Orpyx’s SurroSense Rx® product and future products, such as SurroGait Rx (TM), in New Zealand.
“We are very pleased to see the first of our innovations recognized by the New Zealand intellectual property office,” said Dr. Breanne Everett, CEO of Orpyx Medical Technologies Inc. “Orpyx has made, and continues to make, substantial investment in our intellectual property base, as we lead the world in the development of sensor-based wearable technologies for medical applications.”
SurroSense Rx is designed to actively prevent the complications associated with peripheral neuropathy. The system is comprised of pressure-sensing inserts that wirelessly transmit feedback to the user via a smartwatch or mobile application. The display alerts the user as to when pressure-induced damage is occurring so that behavior can be proactively changed and devastating complications avoided.
About Orpyx Medical Technologies Inc.
Orpyx is a wearable pressure sensor technology company focused on medical applications. To start, Orpyx’s primary intention is to address the world’s growing epidemic of diabetes and its associated complications, most notably, peripheral neuropathy, which leads to lack of circulation, numbness, or loss of protective sensation, in the feet. This problem leads to the development of foot sores-or ulcers-which can ultimately lead to amputation and death infection and ulcers in the feet, also known as peripheral neuropathy. This problem affects upwards of 60% of diabetics over the course of their disease and costs the North American health care system over $16.4 billion annually.